Head & Neck Cancers | Specialty

Monitoring During Active Surveillance and Treatment

March 4th 2015

When to Refer a Patient to a Medical Oncologist

March 4th 2015

Treatments After Progression in DTC

March 4th 2015

Genetic Testing: What Role Do Mutations Play?

March 4th 2015

Interpreting Whole Body Scans

March 4th 2015

Who Are the Best Candidates for TKIs?

March 4th 2015

Approval of Lenvatinib: More Options

March 4th 2015

FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma

February 23rd 2015

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

February 20th 2015

Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC

February 13th 2015

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.

FDA Approves Lenvatinib in Differentiated Thyroid Cancer

February 13th 2015

The FDA has granted approval to lenvatinib (Lenvima) as a treatment for patients with progressive, radioactive iodine-refractory differentiated thyroid cancer.

Sherman Says Lenvatinib Approval "Likely" as FDA Decision Date Nears

February 11th 2015

With a deadline of April 14, the FDA will soon make its final approval decision on the oral multikinase inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

Minimally Invasive Esophagectomy Improves Outcomes, But Remains Underutilized

December 14th 2014

Surgery remains the most effective curative treatment for esophageal cancer. Yet, many eligible patients do not undergo esophagectomy.

Molecular Markers Emerge in the Diagnosis of Thyroid Cancer

December 9th 2014

Although prognostic biomarkers have become increasingly important in the treatment of many types of cancer, no such markers have yet been identified and validated for thyroid cancer.

Three Experts Discuss the Use of Cetuximab in Head and Neck Cancers

November 30th 2014

Cetuximab is the only FDA-approved EGFR inhibitor for the treatment of squamous cell carcinoma of the head and neck.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

November 17th 2014

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma

November 16th 2014

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).

Immunotherapeutic Strategies in Head and Neck Cancer

November 7th 2014

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

Dr. Brose Discusses Lenvatinib and Sorafenib in Differentiated Thyroid Cancer

November 2nd 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.

Dr. Sosa Discusses Molecular Testing in Thyroid Cancer

November 2nd 2014

Julie A. Sosa, MD, MS, professor of surgery and medicine, chief of endocrine surgery, Duke University, discusses molecular testing for thyroid cancer.